BACKGROUND: Despite the high morbidity and mortality of heart failure with preserved ejection fraction (HFpEF), treatment ...

Medera Inc. (“Medera”), a clinical-stage biopharmaceutical company focused on targeting difficult-to-treat and currently ...

Patients with ejection fraction <40% were excluded. Patients were randomized to receive perindopril 2 mg daily or placebo. The primary outcome, the composite of all-cause mortality or unplanned ...

Does finerenone improve outcomes in patients withheart failure (HF) with mildly reduced or preserved ejection fraction?

Objective: To provide an overview of heart failure with preserved ejection fraction (HFPEF), as well as its pathophysiology, diagnosis, and clinical evidence regarding its pharmacologic management.

Eko Health, a leader in artificial intelligence (AI) for the early detection of heart and lung diseases, today announced the ...

UK: A secondary analysis of the FINEARTS-HF randomized clinical trial evaluated the performance of the PREDICT-HFpEF model in ...

"The completion of enrollment in the Phase 1/2a trial marks a crucial milestone for this cardiac gene therapy trial in patients with heart failure with reduced ejection fraction (HFrEF).

Infection-related hospitalization (IRH) is associated with incident heart failure, heart failure with preserved ejection fraction, and heart failure with reduced ejection fraction.